Langzeit-Therapie mit Protonenpumpenhemmern: Wirklich unbedenklich?

Schlüsselwörter

Gastroösophageale Refluxerkrankung - PPI - Gastritis - Nebenwirkungen

Keywords

GERD - PPI - gastritis - adverse events

• Literatur

• 1 Dublin S, Walker RL, Jackson ML et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 792-802
• 2 den Elzen WP, Groeneveld Y, de Ruijter W et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491-497
• 3 Eom CS, Jeon CY, Lim JW et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-319
• 4 Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010; 170: 765-771
• 5 Gulmez SE, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955
• 6 Haag S, Andrews JM, Katelaris PH et al. Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines. Digestion 2009; 80: 226-234
• 7 Hess MW, Hoenderop JG, Bindels RJ et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36: 405-413
• 8 Hutchinson C, Geissler CA, Powell JJ et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56: 1291-1295
• 9 Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy – negative reflux disease: is rebound hypersecretion of acid a problem?. Scand J Gastroenterol 2011; 46: 398-405
• 10 Khalili H, Huang ES, Jacobson BC et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344: e372
• 11 Kwok CS, Arthur AK, Anibueze CI et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-1019
• 12 Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960
• 13 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056
• 14 Lodrup AB, Reimer C, Bytzer P. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment. Scand J Gastroenterol 2013; 48: 515-522
• 15 Lundell L, Havu N, Miettinen P et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006; 23: 639-647
• 16 Ness-Jensen E, Lindam A, Lagergren J et al. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. Gut 2012; 61: 1390-1397
• 17 Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106: 1209-1218
• 18 Poulsen AH, Christensen S, McLaughlin JK et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 2009; 100: 1503-1507
• 19 Robertson DJ, Larsson H, Friis S et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 2007; 133: 755-760
• 20 Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398
• 21 Sarzynski E, Puttarajappa C, Xie Y et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56: 2349-2353
• 22 Van Soest EM, van Rossum LG, Dieleman JP et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966-973
• 23 Targownik LE, Leslie WD, Davison KS et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107: 1361-1369